Hopstem Biotechnology Co., Ltd. Information

Hopstem Bioengineering Co., Ltd. was founded on January 2017 in Hangzhou, by neuroscientists and stem cell biologists from Johns Hopkins University. Hopstem has established world-leading iPSCs platform of neural differentiation and cell engineering. Hopstem has developed several critical patented technologies，as well as CMC platform for iPSC-derived cell therapy products. Hopstem has iPSC reprogramming patent, GMP iPSC line with global licensing rights, iPSC-derived cell product manufacturing and quality system, and a variety of cell therapy products and pipelines, targeting CNS diseases, optical diseases and tumor. Hopstem’s first clinical product - neural progenitor cell hNPC01 targets neural injury diseases such as stroke and traumatic brain injury, has received China's IND approval and entered clinical trials. Hopstem is committed to translating the most cutting-edge technologies to provide global patients with safe, efficient and affordable cell therapy products.